We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in Iranian patients.
- Authors
Eshraghian, Ahad; Taghavi Seyed, Alireza; Nikeghbalian, Saman; Kazemi, Kourosh; Shamsaeefar, Alireza; Mansourian, Mohsenreza; Dehghani, Masoud; Moini, Maryam; Fattahi, Mohammad Reza; Bagheri Lankarani, Kamran; Malekzadeh, Reza; Malek-Hosseini, Seyed Ali
- Abstract
Introduction: A considerable proportion of patients with non-alcoholic fatty liver disease (NAFLD) will progress to non-alcoholic steatohepatitis (NASH) that may eventuate in liver cirrhosis. This study aimed to investigate the status and trend of NASH as an indication for liver transplantation in Iranian patients. Methods: The liver transplant data of all cirrhotic patients who had undergone liver transplantation or who died in transplant waiting list between 2004 and 2016 at Shiraz Organ Transplant Center, Shiraz, Iran were reviewed. The underlying liver diseases leading to liver transplantation were stratified according to year of transplantation and trend of increase or decline were calculated. Patients with cryptogenic liver cirrhosis with body mass index ≥ 30 kg/m2 was defined as modified NASH. Results: Totally 4666 patients with liver cirrhosis were evaluated. 3727 patients underwent liver transplantation and 939 patients passed away. 64 patients with biopsy proven NASH underwent liver transplantation at our center and 27 patients died in waiting list. Mean age and model for end stage liver disease (MELD) were not statistically significant in patients with NASH and modified NASH (P > 0.05). The prevalence of NASH as an indication for liver transplantation in 2011 was 0.59%, in 2012 was 1.05%, in 2013 was 1.45%, in 2014 was 3.8%, in 2015 was 2.7% and in 2016 was 5.65%. The prevalence of modified NASH was 2.08% in 2011, 1.81% in 2012, 2.34% in 2013, 1.97% in 2014, 1.89% in 2015, and 1.86% in 2016. Using Kaplan-Meier curve, mean post-liver transplant survival was 42.38 ± 2.35 months in NASH patients and 47.71 ± 2.98 in modified NASH patients (P = 0.558). Conclusion: This is the largest report of patients with liver cirrhosis showing NASH is a rapidly growing cause of liver cirrhosis and liver transplantation in Iranian patients.
- Subjects
IRAN; CONFERENCES &; conventions; FATTY liver; LIVER transplantation
- Publication
Iranian Journal of Gastroenterology & Hepatology (GOVARESH), 2017, Vol 22, Issue 3, p14
- ISSN
1560-7186
- Publication type
Article